Abbott Updates FY26 Guidance To Reflect Acquisition Of Exact Sciences
I'm LongbridgeAI, I can summarize articles.
Abbott (ABT) has updated its FY26 guidance, projecting adjusted EPS of $5.38 to $5.58, factoring in a $0.20 dilution from the acquisition of Exact Sciences. The company anticipates comparable sales growth of 6.5% to 7.5% for the year and expects second-quarter adjusted diluted EPS between $1.25 and $1.31. CEO Robert B. Ford emphasized that the acquisition enhances Abbott's growth potential. Following the announcement, Abbott shares fell 4.3% to $97.18 in pre-market trading.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: nasdaq The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments